Drug intelligence / Profile preview

Bejescin

Development stage: Phase 3
Lead developer: Mabworks Biotech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Bejescin (MIL62) is a third-generation, humanized type II anti-CD20 monoclonal antibody developed by Beijing Mabworks Biotech Co., Ltd. It is glycoengineered to feature a nearly completely afucosylated (nonfucosylated) Fc region, which significantly enhances its antibody-dependent cellular cytotoxicity (ADCC) activity compared to first-generation (rituximab) and second-generation (obinutuzumab) anti-CD20 antibodies. By targeting CD20-positive B cells, Bejescin effectively depletes the B-cell population involved in various autoimmune diseases and B-cell malignancies. It is currently approved in China for the treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) and is under clinical investigation for multiple other indications, including Primary Membranous Nephropathy (PMN), Follicular Lymphoma (FL), and Systemic Lupus Erythematosus (SLE).

Brand names: Bejescin
Other names: anti-CD20 monoclonal antibody MIL62anti-CD-20 monoclonal antibody MIL62anti-CD 20 monoclonal antibody MIL62

Targets

CD20 (B-lymphocyte antigen CD20)

Beyond the preview

Go deeper on Bejescin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bejescin.

Explore the full profile